Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
Sponsor: Sclnow Biotechnology Co., Ltd.
Summary
The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).
Official title: Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-12-31
Completion Date
2027-12-31
Last Updated
2026-04-23
Healthy Volunteers
No
Conditions
Interventions
Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)
Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 \*10\^6/kg. once a month, total 3 times.
Aspirin Tablet
Drug: Aspirin Tablet, 100 mg/d
Locations (1)
Inner Mongolia International Mongolian Hospital
Hohhot, Inner Mongolia, China